ATE536376T1 - Humanes bindungsmolekül gegen cd1a - Google Patents
Humanes bindungsmolekül gegen cd1aInfo
- Publication number
- ATE536376T1 ATE536376T1 AT04804973T AT04804973T ATE536376T1 AT E536376 T1 ATE536376 T1 AT E536376T1 AT 04804973 T AT04804973 T AT 04804973T AT 04804973 T AT04804973 T AT 04804973T AT E536376 T1 ATE536376 T1 AT E536376T1
- Authority
- AT
- Austria
- Prior art keywords
- human binding
- binding molecules
- binding molecule
- molecule against
- cd1a
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP0351096 | 2003-12-23 | ||
| EP2004052110 | 2004-09-09 | ||
| PCT/EP2004/053639 WO2005063819A2 (en) | 2003-12-23 | 2004-12-21 | Human binding molecule against cd1a |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE536376T1 true ATE536376T1 (de) | 2011-12-15 |
Family
ID=34740629
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04804973T ATE536376T1 (de) | 2003-12-23 | 2004-12-21 | Humanes bindungsmolekül gegen cd1a |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7968092B2 (de) |
| JP (1) | JP4712724B2 (de) |
| AT (1) | ATE536376T1 (de) |
| ES (1) | ES2378767T3 (de) |
| WO (1) | WO2005063819A2 (de) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1539235A2 (de) | 2002-07-01 | 2005-06-15 | Human Genome Sciences, Inc. | Spezifisch an reg iv bindende antikörper |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| EP2902491A1 (de) | 2003-03-19 | 2015-08-05 | Biogen MA Inc. | NOGO Rezeptor bindendes Protein |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP2395016A3 (de) | 2003-05-30 | 2012-12-19 | Merus B.V. | Entwurf und Verwendung von gepaarten unterschiedlichen Regionen von spezifisch bindenden Molekülen |
| EP2322547A1 (de) | 2003-06-25 | 2011-05-18 | Crucell Holland B.V. | Myeloidzellen-spezifisches Lectin |
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ATE536376T1 (de) | 2003-12-23 | 2011-12-15 | Crucell Holland Bv | Humanes bindungsmolekül gegen cd1a |
| EP1776136B1 (de) | 2004-06-24 | 2012-10-03 | Biogen Idec MA Inc. | Behandlung von entmyelinisierenden erkrankungen |
| US8052974B2 (en) | 2005-05-12 | 2011-11-08 | Crucell Holland B.V. | Host cell specific binding molecules capable of neutralizing viruses and uses thereof |
| AU2006269458B2 (en) | 2005-07-08 | 2012-11-08 | Biogen Ma Inc. | Sp35 antibodies and uses thereof |
| CL2007002225A1 (es) * | 2006-08-03 | 2008-04-18 | Astrazeneca Ab | Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un |
| CA2663388C (en) | 2006-09-07 | 2017-01-17 | Crucell Holland B.V. | Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof |
| US8128926B2 (en) | 2007-01-09 | 2012-03-06 | Biogen Idec Ma Inc. | Sp35 antibodies and uses thereof |
| DK2982695T3 (da) | 2008-07-09 | 2019-05-13 | Biogen Ma Inc | Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf |
| CA2791109C (en) | 2011-09-26 | 2021-02-16 | Merus B.V. | Generation of binding molecules |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| NZ702178A (en) | 2012-05-14 | 2017-01-27 | Biogen Ma Inc | Lingo-2 antagonists for treatment of conditions involving motor neurons |
| EP3046629A4 (de) * | 2013-09-20 | 2017-07-12 | Children's Medical Center Corporation | Behandlung von hautentzündungserkrankungen |
| US9603927B2 (en) | 2014-02-28 | 2017-03-28 | Janssen Biotech, Inc. | Combination therapies with anti-CD38 antibodies |
| US9732154B2 (en) | 2014-02-28 | 2017-08-15 | Janssen Biotech, Inc. | Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia |
| EP3191187B1 (de) * | 2014-09-09 | 2021-07-28 | Janssen Biotech, Inc. | Kombinationstherapie mit anti-cd38-antikörpern |
| JP6802791B2 (ja) | 2014-12-04 | 2020-12-23 | ヤンセン バイオテツク，インコーポレーテツド | 急性骨髄性白血病の治療のための抗ｃｄ３８抗体 |
| WO2016112270A1 (en) | 2015-01-08 | 2016-07-14 | Biogen Ma Inc. | Lingo-1 antagonists and uses for treatment of demyelinating disorders |
| JP2018507254A (ja) * | 2015-02-02 | 2018-03-15 | アイツー ファーマシューティカルズ， インコーポレーテッド | 抗代替軽鎖抗体 |
| BR112017024877A2 (pt) | 2015-05-20 | 2019-09-17 | Janssen Biotech, Inc. | anticorpo anti-cd38 e seu uso no tratamento de amiloidose de cadeia leve e outras malignidades hematológicas positivas para cd38 |
| NZ777133A (en) | 2015-06-22 | 2025-05-02 | Janssen Biotech Inc | Combination therapies for heme malignancies with anti-cd38 antibodies and survivin inhibitors |
| US20170044265A1 (en) | 2015-06-24 | 2017-02-16 | Janssen Biotech, Inc. | Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38 |
| MD3827845T2 (ro) | 2015-11-03 | 2022-09-30 | Janssen Biotech Inc | Formulări subcutanate de anticorpi anti-CD38 și utilizări ale acestora |
| US10781261B2 (en) | 2015-11-03 | 2020-09-22 | Janssen Biotech, Inc. | Subcutaneous formulations of anti-CD38 antibodies and their uses |
| WO2017156058A1 (en) * | 2016-03-08 | 2017-09-14 | Janssen Biotech, Inc. | Gitr antibodies, methods, and uses |
| US20190233533A1 (en) | 2016-06-28 | 2019-08-01 | Umc Utrecht Holding B.V. | Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38 |
| EA037973B1 (ru) * | 2016-10-12 | 2021-06-18 | Янссен Байотек, Инк. | Антитела к gitr, способы и применение |
| MA50514A (fr) | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
| CN113439089A (zh) * | 2018-12-31 | 2021-09-24 | 美勒斯公司 | 截短的多价多元体 |
| BR112023005980A2 (pt) | 2020-10-09 | 2023-05-02 | Childrens Medical Center | Anticorpos cd1a e seus usos |
| US12285494B2 (en) | 2021-02-16 | 2025-04-29 | Children's Health Care | Methods for treating B-ALL by administering a pre-BCR complex antagonist |
| JP2024522095A (ja) * | 2021-05-26 | 2024-06-11 | オックスフォード ユニヴァーシティ イノヴェーション リミテッド | 抗体 |
| TW202430550A (zh) | 2022-10-18 | 2024-08-01 | 日商明治製菓藥業股份有限公司 | Ｔ細胞性腫瘤之治療劑 |
| GB202217923D0 (en) * | 2022-11-29 | 2023-01-11 | Univ Oxford Innovation Ltd | Antibodies |
| WO2025146662A1 (en) | 2024-01-05 | 2025-07-10 | Immunocore Limited | Cd1a-pd-1 bispecific agonist for the treatment of atopic dermatitis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010051156A1 (en) * | 2000-04-28 | 2001-12-13 | Defu Zeng | Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions |
| AU2001259230A1 (en) | 2000-04-28 | 2001-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Inhibition of polyclonal b cell activation and immunoglobulin class switching topathogenic autoantibodies by blocking cd1-mediated interactions |
| EP1174440A1 (de) * | 2000-07-19 | 2002-01-23 | U-BISys B.V. | Ein selektiv exprimiertes Epitop auf das menschliches CD38 Molekül detektiert von einem "phage display library"-derivierten menschlichen scFv Antikörperfragment |
| AU2002310222A1 (en) * | 2001-05-31 | 2002-12-09 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
| AU2002361784A1 (en) * | 2001-12-20 | 2003-07-09 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
| ATE536376T1 (de) | 2003-12-23 | 2011-12-15 | Crucell Holland Bv | Humanes bindungsmolekül gegen cd1a |
-
2004
- 2004-12-21 AT AT04804973T patent/ATE536376T1/de active
- 2004-12-21 WO PCT/EP2004/053639 patent/WO2005063819A2/en not_active Ceased
- 2004-12-21 ES ES04804973T patent/ES2378767T3/es not_active Expired - Lifetime
- 2004-12-21 JP JP2006546178A patent/JP4712724B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-23 US US11/387,997 patent/US7968092B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008505605A (ja) | 2008-02-28 |
| US20060257397A1 (en) | 2006-11-16 |
| US7968092B2 (en) | 2011-06-28 |
| WO2005063819A3 (en) | 2005-10-27 |
| JP4712724B2 (ja) | 2011-06-29 |
| WO2005063819A2 (en) | 2005-07-14 |
| ES2378767T3 (es) | 2012-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE536376T1 (de) | Humanes bindungsmolekül gegen cd1a | |
| WO2005000894A3 (en) | Binding molecules for the treatment of myeloid cell malignancies | |
| IL225849A0 (en) | Molecules with binding ability that can neutralize rabies virus, and their uses | |
| EA201201650A1 (ru) | Связывающие молекулы человека, имеющие убивающую активность против стафилококков, и их применения | |
| PH12017502286A1 (en) | Monoclonal antibodies against tissue factor pathway by inhibitor (tfpi) | |
| WO2005012360A3 (en) | Binding molecules against sars-coronavirus and uses thereof | |
| CY1120384T1 (el) | Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων | |
| EA200700175A1 (ru) | Композиции и способы лечения воспалительных заболеваний | |
| EA200870594A1 (ru) | Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение | |
| UA101301C2 (ru) | ВЫДЕЛЕННОЕ АНТИТЕЛО ПРОТИВ IL-23pl 9 И ЕГО ПРИМЕНЕНИЕ | |
| EA200601776A1 (ru) | Метадоновые композиции местного действия и способы их применения | |
| WO2004065423A3 (de) | Erkennungsmoleküle zur behandlung und detektion von tumoren | |
| EA200870019A1 (ru) | Лактамовые соединения и способы их применения | |
| DE502005010615D1 (de) | Mittel zur behandlung von entzündlichen erkrankungen | |
| CY1109741T1 (el) | Sns-595 και μεθοδοι χρησης αυτου | |
| NO20073574L (no) | Triazolsubstituerte aminobenzofenonforbindelser | |
| ATE448232T1 (de) | Substituierte heterozyklen | |
| IL187321A0 (en) | Host cell specific binding molecules capable of neutralizing viruses and uses thereof | |
| WO2005116088A3 (en) | Methods and compositions for treating diseases and disorders associated with siglec-8 expressing cells | |
| NO20055741L (no) | Nye kjemiske forbindelser | |
| GB0418388D0 (en) | Cell therapy | |
| WO2006029176A3 (en) | Cancer-testis antigens | |
| TW200740808A (en) | Inhibiteurs de proteines kinases | |
| WO2004067569A8 (en) | Internalising human binding molecules against cd72 | |
| EA201200182A1 (ru) | Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение |